Acalabrutinib (ACP-196), a Btk Inhibitor, for Treatment of de Novo Activated B-cell (ABC) Subtype of Diffuse Large B-Cell Lymphoma

Completed · Phase 1

Conditions studied: Activated B-cell Diffuse Large B-Cell Lymphoma (ABC DLBCL)

In brief

To characterize the safety profile of acalabrutinib in subjects with relapsed or refractory de Novo Activated B-cell (ABC) Subtype of Diffuse Large B-Cell Lymphoma (DLBCL).

Key facts

Study ID
NCT02112526
Run by
Acerta Pharma BV
People needed
21
Starts
2014-08-07
Expected to finish
2024-10-04
Last updated by the study team
2024-12-20

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

You may not qualify if…

Where it is running

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.